PART 2 | CLEARED STATUS AND NEGATIVE RESULTS |
| Meaning of “cleared status (general)” |
| 6.—(1) For the purposes of these Regulations, an individual is treated as having a cleared status (general) only if he or she is and to the extent certified under this regulation as having a cleared status (general). [S 590/2021 wef 10/08/2021] [S 908/2021 wef 01/12/2021] (2) Where the Director or a recognised medical practitioner is satisfied that an individual is a recovered individual, the Director or recognised medical practitioner (as the case may be) may grant a certificate stating that the individual has a cleared status (general) for a period —| (a) | for a recovered individual who was never vaccinated against a COVID-19 infection before he or she was assessed as having the COVID‑19 infection —| (i) | starting the date the recovered individual first tested positive for SARS-CoV-2 upon undergoing any of the following that led to the assessment of the individual having that infection:| (A) | a polymerase chain reaction test; | | (B) | an antigen rapid test which had been followed by a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection; | | (C) | an antigen rapid test on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms; [S 69/2022 wef 01/02/2022] | | (D) | a serology test in Singapore (whether before, on or after 1 February 2022) that is not attributable to the administration of any vaccine against a COVID-19 infection and without having tested positive for SARS-CoV-2 on any other earlier occasion; [S 69/2022 wef 01/02/2022] [S 102/2022 wef 24/02/2022] | | (E) | an antigen rapid test in Singapore (whether before, on or after 23 February 2022) that is performed by or under the direction of an approved test provider or is self-administered by the individual under the supervision of an approved test provider; and [S 102/2022 wef 24/02/2022] |
[S 9/2022 wef 06/01/2022] [S 102/2022 wef 24/02/2022] | | (ii) | ending on (and including) as follows:| (A) | the 180th day after the date in sub-paragraph (i), unless sub-paragraph (B) applies; | | (B) | 31 January 2022, where the individual is a transitional case; or |
[S 991/2021 wef 01/01/2022] |
[S 590/2021 wef 10/08/2021] [S 102/2022 wef 24/02/2022] | | (b) | for a recovered individual who is assessed as having a COVID‑19 infection after a certificate under this paragraph had been granted in respect of the individual, and who was never vaccinated against a COVID‑19 infection, the period falling after the grant of the certificate —| (i) | starting the date the recovered individual first tested positive for SARS-CoV-2 upon undergoing any of the following that led to the assessment of the individual having that infection:| (A) | a polymerase chain reaction test; | | (B) | an antigen rapid test followed by a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection; | | (C) | an antigen rapid test on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms; [S 102/2022 wef 24/02/2022] | | (D) | an antigen rapid test in Singapore (whether before, on or after 23 February 2022) that is performed by or under the direction of an approved test provider or is self-administered by the individual under the supervision of an approved test provider; and [S 102/2022 wef 24/02/2022] |
[S 9/2022 wef 06/01/2022] [S 102/2022 wef 24/02/2022] | | (ii) | ending on (and including) as follows:| (A) | the 180th day after the date in sub-paragraph (i), unless sub-paragraph (B) applies; | | (B) | 31 January 2022, where the individual is a transitional case. |
[S 991/2021 wef 01/01/2022] |
[S 590/2021 wef 10/08/2021] [S 102/2022 wef 24/02/2022] |
|
(3) Where the Director is satisfied that —| (a) | an individual is a recovered individual; and | | (b) | the individual is vaccinated against a COVID-19 infection by the administration of any approved vaccine by a recognised vaccination provider, |
| the Director may grant a certificate stating that the recovered individual has a cleared status (general) for a period as follows, whichever is applicable: |
| (c) | for an indefinite period starting the day stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination; | | (d) | for a period that starts and ends as stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination. |
[S 91/2022 wef 14/02/2022] |
(4) In addition, where the Director is satisfied that an individual who is a COVID-19 naïve individual is vaccinated against a COVID-19 infection by the administration of any approved vaccine by a recognised vaccination provider, the Director may grant a certificate stating that the individual has a cleared status (general) for a period as follows, whichever is applicable:| (a) | unless sub-paragraph (b) applies —| (i) | for an indefinite period starting the day stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination; or | | (ii) | for a period that starts and ends as stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination; |
| | (b) | if the COVID-19 naïve individual undergoes a primary vaccination before attaining 12 years of age, for a period that —| (i) | starts as stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination; and | | (ii) | ends at the expiry of 2 months after the individual attains 12 years of age or the end date stated in the First Schedule corresponding to the approved vaccine used in the individual’s primary vaccination, whichever date is later. |
[S 180/2022 wef 14/03/2022] |
[S 91/2022 wef 14/02/2022] |
(5) Despite paragraph (2), (3) or (4), where an individual is assessed as having a COVID-19 infection, after he or she underwent vaccination and is granted a certificate under paragraph (3) or (4), the Director or a recognised medical practitioner may, where satisfied that the individual is a recovered individual after that infection or any later infection, grant a certificate stating that the individual has a cleared status (general) for a period as follows, whichever is applicable:| (a) | if the recovered individual underwent only a primary vaccination or was granted a certificate under paragraph (4) stating that the individual has a cleared status (general) for a period of 120 days — for an indefinite period starting the date the recovered individual first tested positive for SARS-CoV-2 upon undergoing any of the following that led to the assessment of the individual having the last infection:| (i) | a polymerase chain reaction test; | | (ii) | an antigen rapid test followed by a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection; | | (iii) | an antigen rapid test on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms; | | (iv) | a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection and without having tested positive for SARS-CoV-2 on any other occasion, but only if such individual was granted a certificate under paragraph (4); | | (v) | an antigen rapid test in Singapore (whether before, on or after 23 February 2022) that is performed by or under the direction of an approved test provider or is self-administered by the individual under the supervision of an approved test provider; [S 102/2022 wef 24/02/2022] |
[S 102/2022 wef 24/02/2022] | | (b) | if the recovered individual was granted a certificate under paragraph (3) for a period mentioned in paragraph (3)(d) — for a period that starts on a relevant date mentioned in sub-paragraph (a) and ends at the expiry of 180 days (including that date) thereafter. |
[S 91/2022 wef 14/02/2022] [S 102/2022 wef 24/02/2022] |
| (5A) [Deleted by S 91/2022 wef 14/02/2022] |
(6) The Director may cancel any certificate granted under this regulation stating that an individual has a cleared status (general) if —| (a) | [Deleted by S 9/2022 wef 06/01/2022] | | (b) | the Director is satisfied that it is the interest of the health and safety of the individual to do so. |
[S 590/2021 wef 10/08/2021] |
| (7) To avoid doubt, the period in paragraph (3), (4) or (5) may be a period before 24 April 2021. [S 590/2021 wef 10/08/2021] |
(8) An individual is a transitional case for the purposes of paragraph (2) —| (a) | if he or she had acquired, before 1 January 2022, a cleared status (general) under paragraph (2), and would have continued on or after that date to have a cleared status (general) if not for the making of the Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) (Amendment No. 14) Regulations 2021; but | | (b) | not if he or she had acquired, before 1 January 2022, a cleared status (general) under paragraph (2) and ceased to have a cleared status (general) that is current before that date because of regulation 8A(1)(a) or (c). |
[S 991/2021 wef 01/01/2022] |
|
| 7. [Deleted by S 991/2021 wef 01/01/2022] |
| Meaning of “cleared status (special)” |
7A.—(1) For the purposes of these Regulations, an individual is treated as having a cleared status (special) only if he or she is and to the extent certified under this regulation as having a cleared status (special).(2) Where the Director or a legally qualified medical practitioner diagnoses that an individual (of any age) without a cleared status (general) that is current, has a severe immunocompromising condition, or is undergoing or about to undergo an immunosuppressive therapy, anticipated to affect the suitability of the individual to be vaccinated against a COVID-19 infection using the nationwide approved vaccines, because the individual —| (a) | has undergone an organ transplant and is or was a recipient of an organ of a human body; | | (b) | is undergoing aggressive immunotherapy; | | (c) | is undergoing or is about to undergo active cancer treatment; or | | (d) | has undergone active cancer treatment, |
| the Director or legally qualified medical practitioner (as the case may be) may grant a certificate stating that the individual has a cleared status (special) for a period corresponding to the period of unsuitability to be so vaccinated — |
| (e) | starting the date the individual is so diagnosed; and | | (f) | ending when the period specified in the certificate expires, being no longer than the applicable period as follows:| (i) | for an individual mentioned in sub-paragraph (a) — 3 months after the date of the individual’s organ transplant operation; | | (ii) | for an individual mentioned in sub‑paragraph (b) or (c) — 365 days after the individual is diagnosed as having a severe immunocompromising condition, or undergoing or about to undergo an immunosuppressive therapy, anticipated to affect the suitability of the individual to be vaccinated against a COVID‑19 infection using the nationwide approved vaccines; | | (iii) | for an individual mentioned in sub-paragraph (d) — 3 months after the date of the last occasion when the individual underwent that active cancer treatment. |
|
|
(3) Where the Director or a legally qualified medical practitioner diagnoses that an individual who is at least 18 years of age has a medical contraindication to vaccination using every nationwide approved vaccine because the individual has or is assessed to be at greater risk of developing —| (a) | an allergic reaction; or | | (b) | a severe adverse reaction that is not an allergic reaction, |
| if administered with a dose of any of the nationwide approved vaccines, the Director or legally qualified medical practitioner (as the case may be) may grant a certificate stating that the individual has a cleared status (special) for a period — |
| (c) | starting the date the individual is so diagnosed; and | | (d) | ending when the period specified in the certificate expires, being no longer than 365 days after that diagnosis. |
|
(4) Where the Director or a legally qualified medical practitioner diagnoses that an individual who is at least 12 years of age but below 18 years of age has a medical contraindication to vaccination using Tozinameran (Pfizer-BioNTech COVID-19 vaccine or Comirnaty COVID-19 vaccine) because the individual has or is assessed to be at greater risk of developing —| (a) | an allergic reaction; or | | (b) | a severe adverse reaction that is not an allergic reaction, |
| if administered with a dose of Tozinameran (Pfizer-BioNTech COVID-19 vaccine or Comirnaty COVID-19 vaccine), the Director or legally qualified medical practitioner (as the case may be) may grant a certificate stating that the individual has a cleared status (special) for a period — |
| (c) | starting the date the individual is so diagnosed; and | | (d) | ending on whichever of the following first occurs:| (i) | when the period specified in the certificate expires, being no longer than 365 days after that diagnosis; or | | (ii) | the individual attains 18 years of age. |
|
|
(5) To avoid doubt —| (a) | the period in paragraph (2), (3) or (4) may consist of a period before 1 December 2021; and | | (b) | the Director or a legally qualified medical practitioner may grant more than one certificate under paragraph (2), (3) or (4) in respect of the same individual upon the expiry of an earlier certificate granted to that individual. |
|
(6) The Director may cancel any certificate granted under this regulation stating that an individual has a cleared status (special) if —| (a) | [Deleted by S 9/2022 wef 06/01/2022] | | (b) | the Director is satisfied that it is the interest of the health and safety of the individual to do so. |
|
[S 908/2021 wef 01/12/2021] |
| Meaning of “cleared status (overseas temporary)” |
7B.—(1) For the purposes of these Regulations, an individual is treated as having a cleared status (overseas temporary) only if he or she is and to the extent certified under this regulation as having a cleared status (overseas temporary).(2) Where the Director is satisfied that an individual (of any age) arriving in Singapore on or after 1 January 2022 —| (a) | is not ordinarily resident in Singapore; | | (b) | is without a cleared status (general) or cleared status (special); and | | (c) | has been administered (whether before, on or after 1 January 2022) an approved vaccine, or a combination of approved vaccines, in any way described in the First Schedule, |
| the Director may, in lieu of the period stated for those approved vaccines in the First Schedule, grant a certificate stating that the individual has a cleared status (overseas temporary) for a period — |
| (d) | starting the time the individual arrives in Singapore; and | | (e) | ending on (and including) the 30th day after the day the individual arrives in Singapore. |
|
(3) The Director may cancel any certificate granted under this regulation stating that an individual has a cleared status (overseas temporary) if any of the following happens:| (a) | [Deleted by S 9/2022 wef 06/01/2022] | | (b) | the individual is granted a cleared status (general); | | (c) | the Director is satisfied that it is the interest of the health and safety of the individual to do so. |
|
| (4) To avoid doubt, the period in paragraph (2) may consist of a period before 1 January 2022. |
[S 991/2021 wef 01/01/2022] |
| What is negative test result |
8.—(1) For the purposes of these Regulations, where an individual undergoes an approved test or tests consisting only of a polymerase chain reaction test or tests, the individual’s test result is treated as negative for SARS-CoV-2 only if —| (a) | the test result from the sole polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV‑2 in that individual or the individual’s test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or [S 590/2021 wef 10/08/2021] | | (b) | the test result from the last polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV‑2 in that individual, after the individual undergoes further polymerase chain reaction tests and the test results of those tests are uncertain or invalid except the last, or the individual’s last test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2. [S 590/2021 wef 10/08/2021] |
(2) For the purposes of these Regulations, where an individual undergoes an approved test or tests consisting only of an antigen rapid test or tests, the individual’s test result is treated as negative for SARS‑CoV‑2 only if —| (a) | the antigen rapid test result from the sole antigen rapid test the individual undergoes shows no presence of SARS‑CoV‑2 in that individual; or | | (b) | the test result from the last antigen rapid test the individual undergoes shows no presence of SARS‑CoV‑2 in that individual, after the individual undergoes further antigen rapid tests and the test results of those tests are uncertain or invalid except the last. [S 768/2021 wef 11/10/2021] |
|
(3) For the purposes of these Regulations, where an individual undergoes a series of approved tests consisting of polymerase chain reaction tests and antigen rapid tests, the individual’s test result is treated as negative for SARS‑CoV-2 only if —| (a) | the test results of the antigen rapid tests are uncertain or invalid, another respiratory specimen from the individual is then subjected to a polymerase chain reaction test, and —| (i) | the test result from that polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV-2 in that individual or the individual’s test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or [S 590/2021 wef 10/08/2021] | | (ii) | the test result from the last polymerase chain reaction test the individual undergoes shows no presence of SARS-CoV-2 in that individual, after the individual undergoes further polymerase chain reaction tests and the test results of those tests are uncertain or invalid except the last, or the individual’s last test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or [S 590/2021 wef 10/08/2021] |
[S 768/2021 wef 11/10/2021] | | (b) | the test result of an antigen rapid test shows the presence of SARS‑CoV-2 in that individual, another respiratory specimen from the individual is then subjected to a polymerase chain reaction test, and —| (i) | the test result from that polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV-2 in that individual or the individual’s test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or [S 590/2021 wef 10/08/2021] | | (ii) | the test result from the last polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV-2 in that individual, after the individual undergoes further polymerase chain reaction tests and the test results of those tests are uncertain or invalid except the last, or the individual’s last test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2. [S 590/2021 wef 10/08/2021] |
|
|
(4) Despite paragraphs (1), (2) and (3), a result of an antigen rapid test for the presence of SARS‑CoV-2 applied to an individual’s respiratory specimen must be disregarded for the purposes of these Regulations if —| (a) | the relevant sampling activity taking the respiratory specimen from the individual was —| (i) | not performed in Singapore, or not performed by or under the direction of an approved test provider where the relevant sampling activity is not self-administered; or | | (ii) | in the case of a self-administered relevant sampling activity performed by the individual on himself or herself, not supervised by an approved test provider; or |
[S 768/2021 wef 11/10/2021] | | (b) | the relevant testing activity or the relevant assessment activity involving the respiratory specimen from the individual was —| (i) | not performed in Singapore, or not performed by or under the direction of an approved test provider where the relevant testing activity or the relevant assessment activity is not self-administered; or | | (ii) | in the case of a self-administered relevant testing activity or a self-administered relevant assessment activity performed by the individual involving the respiratory specimen removed from himself or herself, not supervised by an approved test provider. |
[S 768/2021 wef 11/10/2021] |
|
|
| When is cleared status current |
8A.—(1) For the purposes of these Regulations, an individual who has a cleared status (general) because he or she is granted a certificate under regulation 6(2) does not have a cleared status (general) that is current —| (a) | after the end of the period specified in and applicable to the individual under regulation 6(2); or [S 69/2022 wef 01/02/2022] | | (b) | [Deleted by S 69/2022 wef 01/02/2022] | | (c) | after the certificate under regulation 6(2) is cancelled. |
(2) For the purposes of these Regulations, an individual who has a cleared status (general) other than for an indefinite period because he or she is granted a certificate under regulation 6(3), (4) or (5) does not have a cleared status (general) that is current —| (a) | after the end of the period referred to in and applicable to the individual under regulation 6(3), (4) or (5), as the case may be; or [S 69/2022 wef 01/02/2022] | | (b) | [Deleted by S 69/2022 wef 01/02/2022] | | (c) | after the cancellation of the certificate under regulation 6(3), (4) or (5), as the case may be. |
[S 991/2021 wef 01/01/2022] [S 91/2022 wef 14/02/2022] |
| (3) For the purposes of these Regulations, an individual who has a cleared status (general) for an indefinite period because he or she is granted a certificate under regulation 6(3), (4) or (5) does not have a cleared status (general) that is current after the cancellation of the certificate under regulation 6(6). [S 91/2022 wef 14/02/2022] |
(3A) For the purposes of these Regulations, an individual who has a cleared status (special) because he or she is granted a certificate under regulation 7A(2), (3) or (4) does not have a cleared status (special) that is current —| (a) | after the end of the period referred to in and applicable to the individual under regulation 7A(2), (3) or (4), as the case may be; or [S 69/2022 wef 01/02/2022] | | (b) | [Deleted by S 69/2022 wef 01/02/2022] | | (c) | after the cancellation under regulation 7A(6) of the certificate. |
[S 908/2021 wef 01/12/2021] |
(3B) For the purposes of these Regulations, an individual who has a cleared status (overseas temporary) because he or she is granted a certificate under regulation 7B(2) does not have a cleared status (overseas temporary) that is current —| (a) | after the end of the 30th day mentioned in and applicable to the individual under regulation 7B(2); or [S 69/2022 wef 01/02/2022] | | (b) | [Deleted by S 69/2022 wef 01/02/2022] | | (c) | after the cancellation under regulation 7B(3) of the certificate. |
[S 991/2021 wef 01/01/2022] |
| (4) [Deleted by S 69/2022 wef 01/02/2022] |
| (5) [Deleted by S 69/2022 wef 01/02/2022] |
[S 590/2021 wef 10/08/2021] |
|